INT14207

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.67
First Reported 1990
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 20
Total Number 20
Disease Relevance 5.76
Pain Relevance 7.64

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

enzyme binding (DNM2) GTPase activity (DNM2) cytoplasm (DNM2)
cytosol (DNM2) signal transduction (DNM2) nucleus (DNM2)
Anatomy Link Frequency
vesicles 2
keratinocytes 2
pits 2
caudate nucleus 1
dentate gyrus 1
DNM2 (Homo sapiens)
Pain Link Frequency Relevance Heat
Dynorphin 48 100.00 Very High Very High Very High
Kappa opioid receptor 42 100.00 Very High Very High Very High
Opioid 30 100.00 Very High Very High Very High
substance P 2 99.40 Very High Very High Very High
imagery 122 98.98 Very High Very High Very High
Nucleus accumbens 4 97.16 Very High Very High Very High
Hippocampus 4 95.72 Very High Very High Very High
Potency 12 90.44 High High
Central nervous system 2 81.88 Quite High
pruritus 6 80.68 Quite High
Disease Link Frequency Relevance Heat
Infection 324 100.00 Very High Very High Very High
Epilepsy 16 99.76 Very High Very High Very High
Channelopathies 5 99.12 Very High Very High Very High
Muscle Disease 51 97.92 Very High Very High Very High
Lung Cancer 6 91.52 High High
Pruritus 10 87.44 High High
Eczema 12 87.28 High High
Cancer 4 85.64 High High
Hypopituitarism 3 68.80 Quite High
Targeted Disruption 4 62.40 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Substantial differences in products and especially in the rate of biotransformation were observed between the processing of Dyn A(1-17) and the two shorter Dyn A peptides, Dyn A(1-13) and Dyn A(1-10)amide.
Gene_expression (processing) of Dyn
1) Confidence 0.67 Published 1996 Journal Peptides Section Abstract Doc Link 8899817 Disease Relevance 0 Pain Relevance 0.11
To further validate the findings obtained from the initial screen, we have selected these genes (CLTC, AP2B1, DNM2, ARRB1, ATP6V0A1 & ARPC1B) for re-confirming their inhibitory effects on DENV infection.
Gene_expression (infection) of DNM2 associated with infection
2) Confidence 0.48 Published 2010 Journal Virol J Section Body Doc Link PMC2825209 Disease Relevance 0.53 Pain Relevance 0
Very few Dyn-IR structures were present in the molecular and granule cell layers of the dentate gyrus.
Gene_expression (present) of Dyn-IR in dentate gyrus
3) Confidence 0.48 Published 1990 Journal J. Neurosci. Section Abstract Doc Link 1688934 Disease Relevance 0.44 Pain Relevance 0.21
In contrast, in all TLE specimens, Dyn-IR elements were present in these layers.
Gene_expression (present) of Dyn-IR associated with epilepsy
4) Confidence 0.48 Published 1990 Journal J. Neurosci. Section Abstract Doc Link 1688934 Disease Relevance 0.44 Pain Relevance 0.20
Immunoreactive Big Dyn was detected using the combination of radioimmunoassay (RIA) and HPLC in the human nucleus accumbens, caudate nucleus, hippocampus and cerebrospinal fluid (CSF) with the ratio of Big Dyn and Dyn B being approximately 1:3.
Gene_expression (detected) of Dyn in cerebrospinal fluid associated with nucleus accumbens and hippocampus
5) Confidence 0.44 Published 2006 Journal J. Neurochem. Section Abstract Doc Link 16515546 Disease Relevance 0 Pain Relevance 0.78
Typical muscle imaging findings of patients with proven mutations in the DNM2, SEPN1, ACTA1, RYR1 and collagen 6A1 are provided

Muscle channelopathies and metabolic myopathies

Gene_expression (6A1) of DNM2 in muscle associated with muscle disease, channelopathies and imagery
6) Confidence 0.41 Published 2010 Journal Eur Radiol Section Body Doc Link PMC2940021 Disease Relevance 0.99 Pain Relevance 0.13
We studied further the role of the clathrin endocytic pathway by knocking down the expression of dynamin-2 (Dyn-2), a key protein required for the formation of clathrin-coated pits and vesicles, and of caveolae [18,36,37].
Gene_expression (expression) of dynamin-2 in vesicles
7) Confidence 0.35 Published 2007 Journal PLoS Pathogens Section Body Doc Link PMC1904475 Disease Relevance 0.26 Pain Relevance 0
We studied further the role of the clathrin endocytic pathway by knocking down the expression of dynamin-2 (Dyn-2), a key protein required for the formation of clathrin-coated pits and vesicles, and of caveolae [18,36,37].
Gene_expression (expression) of Dyn-2 in vesicles
8) Confidence 0.35 Published 2007 Journal PLoS Pathogens Section Body Doc Link PMC1904475 Disease Relevance 0.26 Pain Relevance 0
Transduction of HeLa cells inhibited Dyn-2 expression in EGFP+ cells (Figure 7C), with the expected functional implications, as evidenced by a significant increase in transferrin receptor surface expression (Figure 7C).
Gene_expression (expression) of Dyn-2 in HeLa
9) Confidence 0.35 Published 2007 Journal PLoS Pathogens Section Body Doc Link PMC1904475 Disease Relevance 0.21 Pain Relevance 0
Moreover, chromograninA-immunoreactive pulmonary neuroendocrine cells expressing DYN were close to substance P- and KOR-immunoreactive sensory nerves.
Gene_expression (expressing) of DYN in neuroendocrine cells associated with dynorphin, kappa opioid receptor and substance p
10) Confidence 0.33 Published 2010 Journal Histol. Histopathol. Section Abstract Doc Link 20376782 Disease Relevance 0.38 Pain Relevance 0.68
Double immunofluorescence microscopy analysis revealed colocalization of the opioid precursor PDYN with its end-product DYN, and key processing enzymes prohormone convertases 1 and 2 and carboxypeptidase E, as well as the kappa-opioid receptor (KOR) within alveolar macrophages and cancerous cells in varying degrees among patients.
Gene_expression (product) of DYN in alveolar macrophages associated with dynorphin, kappa opioid receptor and opioid
11) Confidence 0.29 Published 2010 Journal Histol. Histopathol. Section Abstract Doc Link 20376782 Disease Relevance 0.42 Pain Relevance 0.69
Lentiviral vectors expressing GFP and shRNA (against Dyn-2 or an irrelevant protein as a control) were produced and used as described [39].



Gene_expression (expressing) of Dyn-2
12) Confidence 0.27 Published 2007 Journal PLoS Pathogens Section Body Doc Link PMC1904475 Disease Relevance 0.08 Pain Relevance 0
Another major pathway of Dyn A (1-17) biotransformation is cleavage of the peptide linkage between Arg(6) and Arg(7) to produce the opioid peptide, Dyn A (1-6), and the nonopioid peptide, Dyn A (7-17).
Gene_expression (produce) of Dyn in cleavage associated with opioid
13) Confidence 0.19 Published 1996 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 8930152 Disease Relevance 0 Pain Relevance 0.35
Immunoreactive Big Dyn was detected using the combination of radioimmunoassay (RIA) and HPLC in the human nucleus accumbens, caudate nucleus, hippocampus and cerebrospinal fluid (CSF) with the ratio of Big Dyn and Dyn B being approximately 1:3.
Gene_expression (detected) of Dyn in nucleus accumbens associated with nucleus accumbens and hippocampus
14) Confidence 0.15 Published 2006 Journal J. Neurochem. Section Abstract Doc Link 16515546 Disease Relevance 0 Pain Relevance 0.78
Immunoreactive Big Dyn was detected using the combination of radioimmunoassay (RIA) and HPLC in the human nucleus accumbens, caudate nucleus, hippocampus and cerebrospinal fluid (CSF) with the ratio of Big Dyn and Dyn B being approximately 1:3.
Gene_expression (detected) of Dyn in hippocampus associated with nucleus accumbens and hippocampus
15) Confidence 0.15 Published 2006 Journal J. Neurochem. Section Abstract Doc Link 16515546 Disease Relevance 0 Pain Relevance 0.78
Immunoreactive Big Dyn was detected using the combination of radioimmunoassay (RIA) and HPLC in the human nucleus accumbens, caudate nucleus, hippocampus and cerebrospinal fluid (CSF) with the ratio of Big Dyn and Dyn B being approximately 1:3.
Gene_expression (detected) of Dyn in caudate nucleus associated with nucleus accumbens and hippocampus
16) Confidence 0.15 Published 2006 Journal J. Neurochem. Section Abstract Doc Link 16515546 Disease Relevance 0 Pain Relevance 0.78
We studied further the role of the clathrin endocytic pathway by knocking down the expression of dynamin-2 (Dyn-2), a key protein required for the formation of clathrin-coated pits and vesicles, and of caveolae [18,36,37].
Gene_expression (expression) of Dyn-2 in pits
17) Confidence 0.12 Published 2007 Journal PLoS Pathogens Section Body Doc Link PMC1904475 Disease Relevance 0.26 Pain Relevance 0
We studied further the role of the clathrin endocytic pathway by knocking down the expression of dynamin-2 (Dyn-2), a key protein required for the formation of clathrin-coated pits and vesicles, and of caveolae [18,36,37].
Gene_expression (expression) of dynamin-2 in pits
18) Confidence 0.12 Published 2007 Journal PLoS Pathogens Section Body Doc Link PMC1904475 Disease Relevance 0.26 Pain Relevance 0
The analyses revealed that epidermal keratinocytes express kappa-opioid receptor and its ligands, DynA (1-17) and DynA (1-8).
Gene_expression (express) of DynA in keratinocytes associated with kappa opioid receptor
19) Confidence 0.04 Published 2007 Journal J. Invest. Dermatol. Section Abstract Doc Link 17611580 Disease Relevance 0.62 Pain Relevance 1.08
The analyses revealed that epidermal keratinocytes express kappa-opioid receptor and its ligands, DynA (1-17) and DynA (1-8).
Gene_expression (express) of DynA in keratinocytes associated with kappa opioid receptor
20) Confidence 0.04 Published 2007 Journal J. Invest. Dermatol. Section Abstract Doc Link 17611580 Disease Relevance 0.62 Pain Relevance 1.09

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox